New American Thyroid Association and American Association of Clinical Endocrinologists Guidelines for Thyrotoxicosis and Other Forms of Hyperthyroidism: Significant Progress for the Clinician and a Guide to Future Research
2011; Mary Ann Liebert, Inc.; Volume: 21; Issue: 6 Linguagem: Inglês
10.1089/thy.2011.0104
ISSN1557-9077
AutoresElizabeth N. Pearce, James V. Hennessey, Michael T. McDermott,
Tópico(s)Neuroendocrine Tumor Research Advances
ResumoThyroidVol. 21, No. 6 EditorialsFree AccessNew American Thyroid Association and American Association of Clinical Endocrinologists Guidelines for Thyrotoxicosis and Other Forms of Hyperthyroidism: Significant Progress for the Clinician and a Guide to Future ResearchElizabeth N. Pearce, James V. Hennessey, and Michael T. McDermottElizabeth N. PearceBoard of Directors, American Thyroid Association.Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, Boston, Massachusetts.Search for more papers by this author, James V. HennesseyHarvard Medical School, Boston, Massachusetts.Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.Search for more papers by this author, and Michael T. McDermottSection of Endocrinology, Metabolism, and Diabetes, University of Colorado Hospital, Denver, Colorado.Search for more papers by this authorPublished Online:10 Jun 2011https://doi.org/10.1089/thy.2011.0104AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail The authors of the new American Thyroid Association (ATA) and American Association of Clinical Endocrinologists (AACE) guidelines for hyperthyroidism and other forms of thyrotoxicosis, published in this issue (1), are to be congratulated. These guidelines are much needed. They serve to update separate previous guidelines from the ATA in 1995 (2) and from AACE in 2002 (3). The updated version is far more comprehensive than the older versions, including topics such as thyroiditis, gestational thyrotoxicosis, surgical preparation and extent, and radiation safety, which were not previously discussed. The new guidelines are also more modern in format, incorporating separate recommendations together with levels of evidence.An important shortcoming of the new guidelines is that they are based on relatively limited available evidence. Of the 100 graded recommendations, 80 are strong recommendations (grade 1) and 20 are weak recommendations (grade 2). Seventy are based on low-quality evidence (+), 29 are based on moderate-quality evidence (++), and only one is based on high-quality evidence (+++). Of the 80 strong recommendations, 56 (70%) are based on low-quality evidence (+), 23 (29%) are based on moderate-quality evidence (++), and only one (1%) is based on high-quality evidence (+++). Of the 20 weak recommendations, 15 (75%) are based on low-quality evidence (+) and five (25%) are based on moderate-quality evidence (++). Therefore, most are strong recommendations that are based on low-quality evidence. This indicates that clinical management of hyperthyroidism is still largely rooted in expert opinion and personal experience. Given this, it is perhaps remarkable that 98 of the recommendations were unanimous, whereas two of the recommendations had a single dissenting member.One goal of this editorial is to explore areas where we three editorialists disagreed with the recommendations and with each other. One minor area of disagreement among us relates to determining the etiology of thyrotoxicosis. All of us appreciate the guidelines' emphasis on the use of the radioactive iodine uptake when the etiology of hyperthyroidism is not clinically apparent. However, one of us feels that, given concerns about unnecessary medical radiation exposure and costs, thyroid receptor antibody (TRAb) testing should be considered as an alternative to nuclear medicine testing in all patients, not just pregnant and nursing women. All of us are united in the hope that these guidelines will help to decrease the ordering of unnecessary iodinated contrast imaging in hyperthyroid patients, an all-too-frequent practice that delays subsequent radioactive iodine imaging or treatment.With regard to ruling out factitious thyrotoxicosis, we would add that the triiodothyronine (T3)/thyroxine (T4) ratio is typically 20 with excess T3 ingestion, but it may be unhelpful in thyroid hormone extract ingestion because the T4/T3 ratios of thyroid hormone extract products may be inconsistent. Although the U.S. Food and Drug Administration has warned against this practice, manufacturers have previously marketed 3,5,3′-triiodothyroacetic acid (TRIAC)-containing supplements as weight loss aids. High TRIAC doses would be expected to cause low serum thyrotopin (TSH) and T4 levels, but elevated serum T3 due to cross-reactivity of TRIAC with T3 assays (4). The suggestion to check fecal T4 levels to rule out factitious thyrotoxicosis in thyroglobulin antibody positive patients is both novel and helpful.The previous AACE guidelines noted that "in the U.S. radioactive iodine is currently the treatment of choice for Graves'" and largely ignored other treatment options. The new guidelines give more equal and balanced consideration to I-131, anti-thyroid drugs (ATDs), and surgery in the management of Graves' disease. We applaud Recommendation 4, with its emphasis on individualizing the management plan with proper attention paid to the preferences of each patient.Although all therapeutic options are recognized, we believe that the duration of ATD use is appropriately limited under the current guidelines. Definitive therapy is preferred in Graves' disease patients whose disease does not remit after 12–18 months of ATD treatment and in all patients with toxic nodules, given the potential for ATD-related adverse effects even after prolonged use. Although the guidelines state that the prolonged use of ATDs is acceptable when patients "prefer this approach," we all strongly discourage this, especially in patients taking higher ATD doses (>15 mg/d methimazole [MMI]). In this situation, we feel most comfortable documenting that another course has been suggested, but that the patient has refused definitive therapy. In this case we do not believe that the customer is always right.The previous AACE guidelines did not comment on the duration of ATD therapy or on differences between propylthiouracil (PTU) and MMI. The 1995 ATA guidelines were more forthcoming about ATD use, but there have been several important changes in recommendations regarding anti-thyroid drug therapy since 1995. PTU is now considered to be a second-line agent except during the first trimester of pregnancy or in thyroid storm. All of us disagree with the implication that MMI should be avoided in favor of PTU in patients with thyroid storm because there is no clear evidence to indicate that PTU is more effective than MMI in this setting (5). There is always concern for adverse reactions or inadequate therapy when switching from one ATD to another. The guidelines recommend against changing from one ATD to another in the setting of serious adverse skin reactions or agranulocytosis. However, switching from PTU to MMI is recommended for patients with liver function abnormalities, as is changing from MMI to PTU for the first trimester of pregnancy.The optimal duration of ATD therapy has been narrowed from the 6–24 months previously advocated to 12–18 months. Block-replace therapy, previously presented as a reasonable option, is now specifically proscribed.A new recommendation (Recommendation 20) promotes measurement of TRAb prior to stopping ATDs. We find it somewhat perplexing that measurement of TRAb is recommended before weaning patients off ATD therapy, but not at diagnosis or prior to initiation of therapy. With regard to TRAb measurement prior to the discontinuation of ATDs, the guidelines do not clearly discuss the best course of action if the TRAb is clearly elevated. In this instance, should ATDs be continued? Should the dose be increased? Should definitive therapy be instituted? Should ATDs be discontinued with closer follow-up? We would favor discontinuation of ATD therapy and institution of definitive therapy but believe that further clinical studies are warranted to determine the best course of action.The prior ATA guidelines mentioned the use of beta blockers for symptomatic relief but did not provide specific information about their most appropriate use. In the current guidelines, the difference between the strong recommendations for beta blockers (Recommendations 5 and 32) and the weak recommendations for methimazole (Recommendations 6 and 33) pretreatment prior to I-131 treatment in at-risk patients (not all patients) is the result of the dissent of just one panel member. We don't agree with this distinction. Furthermore, in Recommendation 60, both beta blockers and MMI are recommended prior to I-131 in children with severe hyperthyroidism. The reason for the difference in the recommendation strength between adults and children is not clear. While many patients require no pretreatment with either drug, all of us personally recommend pretreatment of all high risk patients with both beta blockers and MMI.Plasmapheresis is a therapeutic option not mentioned at all in the guidelines. We would note that plasmapheresis has been reported to reduce or normalize thyroid hormone levels preoperatively in patients who cannot take ATD therapy (6,7). Its successful use has also been reported in patients with thyroid storm (8). As such, mention of plasmapheresis is warranted to assure awareness of this effective, albeit rarely applied, therapy.A significant departure from previous guidelines is the explicit statement that the goal of I-131 therapy in Graves' disease is hypothyroidism. This is helpful in setting appropriate patient and provider expectations. We also find the discussion regarding the use of ATDs in toxic multinodular goiter to raise serum TSH and enhance uptake for enhanced tissue killing with 131 I to be particularly clinically useful.The recommendations regarding safety precautions following radioactive iodine therapy are important, particularly in light of current variable practice patterns around the United States (9). A detailed ATA Best Practices statement regarding safety precautions following I-131 dosing has recently been published (10). One caveat with regard to the guidelines is that it is stated, based on Nuclear Regulatory Commission (NRC) rules, that discharge precautions after I-131 pertain only to patients with retained doses >33 mCi. Doses used in patients with hyperthyroidism are typically lower than this threshold. However, it would be unfortunate if this literal interpretation of the NRC rule were to downplay the importance of the radiation safety precautions following I-131 therapy for hyperthyroidism. Precautions remain important even when lower I-131 doses are administered. The retained radiation dose lasts longer in hyperthyroid patients than in thyroid cancer patients. Hyperthyroid patients are often young enough to have small children at home who are at particular risk from radiation exposure. Finally, the careful observation of precautions helps to alleviate fears about radiation exposure among the lay public.One discrepancy in the guidelines is between Recommendation 37, which advocates following free T4, total T3, and TSH in the post I-131 monitoring of patients with multinodular goiter and toxic adenoma, and Recommendation 11, which advocates only free T4 and total T3, but not TSH testing, in the post I-131 follow-up of Graves' disease patients. Following I-131, TSH may be suppressed for up to 6 weeks after T4 and T3 normalize, but it is not clear that Graves' disease and toxic nodular disease are different in this regard. We would recommend free T4, total T3, and TSH testing in all these situations.Detailed recommendations regarding the pre- and postoperative care of patients who undergo thyroidectomy are clinically valuable. An important distinction is made between Graves' disease patients, who should receive iodine preoperatively to decrease thyroid vascularity, and patients with autonomous nodular goiter, who should not receive preoperative iodine due to the risk of precipitating Jöd-Basedow disease.It is interesting to note that total thyroidectomy is preferred in toxic adenoma patients when any abnormality requiring future surveillance is present in the contralateral lobe. We often have difficulty convincing patients with known thyroid cancer that completion thyroidectomy is their best option, whereas here the intentional resection of benign tissue is, justifiably, advocated.Regarding postoperative care, Recommendation 26 suggests that either serum calcium or parathyroid hormone (PTH) should be monitored in the postoperative setting. We do not feel that these tests are interchangeable. Serum calcium values (corrected for albumin levels) are both less expensive and more useful than serum PTH for acute clinical decision-making. There is a risk that appropriately low serum PTH levels in those discharged on calcium and calcitriol may be misinterpreted as permanent hypoparathyroidism. In addition, serum parathyroid hormone levels within the normal range may be misleading (11).The section on the management of subclinical hyperthyroidism is a particularly welcome addition to the new guidelines. This topic was not addressed at all in the 1995 ATA guidelines. Previous consensus statements (12,13) and the previous AACE guidelines noted that this area is controversial and therapeutic options should be individualized. The prior publications all recommended consideration of treatment for subclinical hyperthyroidism (when the serum TSH is persistently <0.1 mIU/L) for those with symptoms, atrial fibrillation, osteoporosis, or osteopenia. The new guidelines are more aggressive in adding consideration of treatment in any patient if the underlying etiology is toxic nodular disease, and in all individuals aged ≥65 and all postmenopausal women not on bisphosphonates or estrogen.Another useful addition to the new guidelines is the discussion regarding iodine-induced hyperthyroidism. The guidelines state that "iodine-containing contrast agents may be an additional factor in the development of thyroid storm in patients with illnesses unrelated to thyroid disease," implying that contrast administration to patients without underlying thyroid disease may lead to storm. However, the majority of case reports about the induction of storm with contrast are in subjects with underlying subclinical thyrotoxicosis from toxic adenoma or toxic multinodular goiter. It would be unusual to induce severe thyrotoxicosis in otherwise normal thyroids with iodinated contrast. In addition, the guidelines may downplay the time to clearance of an iodinated contrast load. We have observed that after contrast administration, especially with repeated catheterization or angiography or in the setting of mild renal compromise, the iodine load may take up to several months to clear. While the guidelines note that a urinary iodine concentration may be used to determine whether the iodine load is too high for radioactive iodine scanning or therapy, no threshold values are provided. Based on anecdotal evidence we would suggest that it is reasonable to proceed with radioactive iodine scanning or treatment after a known iodine load if the urinary iodine concentration is under 200 μg/L.Although commonly encountered in clinical practice, the treatment of thyroid disease in pregnancy is clearly an understudied topic. In the current guidelines, 11 of 12 recommendations (86%) focused on hyperthyroidism in pregnancy were strong recommendations despite all 12 recommendations being based on low-quality evidence. A significant departure from previous guidelines is the recommendation for the use of PTU as a first-line ATD only in the first trimester of pregnancy; previously, PTU had been preferred throughout gestation. We all share concerns about Recommendation 68, which advocates the use of trimester-specific free T3 or free T4 assays in the diagnosis of hyperthyroidism. Both measurements, but particularly commercially available free T3 assays, are problematic in pregnant women, and trimester-specific ranges are not widely available.Recommendations for the diagnosis and treatment of postpartum thyroiditis are included in these guidelines for the first time. However, the guidelines are somewhat unclear regarding the expected duration of thyroid dysfunction, the potential duration of LT4 therapy for the symptomatic hypothyroid phase, and the likelihood that permanent hypothyroidism might be present after withdrawal. New ATA guidelines for the management of thyroid disease in pregnancy and the postpartum period are currently being considered for publication and should provide more detailed recommendations. The current guidelines do have useful information regarding the use of Tc99 or I-123 (never I-131) in the diagnosis of postpartum thyroiditis. Specific advice about the number of days to avoid breastfeeding following nuclear medicine studies would have been helpful.Finally, the new guidelines include a useful section on Graves' orbitopathy. The previous ATA guidelines recommended corticosteroids with I-131 treatment in all patients with established ophthalmopathy, regardless of severity or activity. The previous AACE guidelines noted that "systemic glucocorticoids have been used … in patient with active ophthalmopathy … particularly after I-131 therapy, but their efficacy is not fully established." The updated guidelines now, more helpfully, state that those with mild active Graves' orbitopathy who are smokers or those with moderate to severe active Graves' orbitopathy should receive glucocorticoids with I-131 treatment.The lack of high-quality evidence regarding the management of hyperthyroidism underscores the need for more clinical and translational research. It is hoped that, in addition to serving as a clinical tool, these guidelines may be used to help identify gaps in the literature and to direct research that will provide answers to persistent management questions in this important disease that affects 1%–2% of the population.Author Disclosure StatementNo competing financial interests exist. E.N.P. has previously approved the hyperthyroid guidelines as a member of the ATA board of directors.References1 ATA/AACE Taskforce on Hyperthyroidism and Other Causes of ThyrotoxicosisBahn RSBurch HBCooper DSGarber JRGreenlee MCKlein ILaurberg PMcDougall RMontori VMRivkees SARoss DSSosa JAStan MN2011Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical EndocrinologistsThyroid21593646.1. ATA/AACE Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis; Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall R, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN 2011 Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593–646. Link, Google Scholar2 Singer PACooper DSLevy EGLadenson PWBraverman LEDaniels GGreenspan FSMcDougall IRNikolai TF1995Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid AssociationJAMA273808812.2. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF 1995 Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 273:808–812. Crossref, Medline, Google Scholar3 Baskin HJCobin RHDuick DSGharib HGuttler RBKaplan MMSegal RL2002American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidismEndocr Pract8457469.3. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL 2002 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 8:457–469. Crossref, Medline, Google Scholar4 American Thyroid Association2000ATA supports FDA warning on Triax, February 26, 2000www.thyroid.org/professionals/publications/statements/00_02_26_triax.htmlApril252011.4. American Thyroid Association 2000 ATA supports FDA warning on Triax, February 26, 2000. Available at www.thyroid.org/professionals/publications/statements/00_02_26_triax.html, accessed April 25, 2011. Google Scholar5 Cooper DS2005Antithyroid drugsN Engl J Med352905917.5. Cooper DS 2005 Antithyroid drugs. N Engl J Med 352:905–917. Crossref, Medline, Google Scholar6 Ezer ACaliskan KParlakgumus ABelli SKozanoglu IYildirim S2009Preoperative therapeutic plasma exchange in patients with thyrotoxicosisJ Clin Apher24111114.6. Ezer A, Caliskan K, Parlakgumus A, Belli S, Kozanoglu I, Yildirim S 2009 Preoperative therapeutic plasma exchange in patients with thyrotoxicosis. J Clin Apher 24:111–114. Crossref, Medline, Google Scholar7 Guvenc BUnsal CGurkan EDincer S2004Plasmapheresis in the treatment of hyperthyroidism associated with agranulocytosis: a case reportJ Clin Apher19148150.7. Guvenc B, Unsal C, Gurkan E, Dincer S 2004 Plasmapheresis in the treatment of hyperthyroidism associated with agranulocytosis: a case report. J Clin Apher 19:148–150. Crossref, Medline, Google Scholar8 Vyas AAVyas PFillipon NLVijayakrishnan RTrivedi N2010Successful treatment of thyroid storm with plasmapheresis in a patient with methimazole-induced agranulocytosisEndocr Pract16673676.8. Vyas AA, Vyas P, Fillipon NL, Vijayakrishnan R, Trivedi N 2010 Successful treatment of thyroid storm with plasmapheresis in a patient with methimazole-induced agranulocytosis. Endocr Pract 16:673–676. Crossref, Medline, Google Scholar9 Greenlee CBurmeister LAButler RSEdinboro CHMorrison SMMilas M2011Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitionersThyroid21151160.9. Greenlee C, Burmeister LA, Butler RS, Edinboro CH, Morrison SM, Milas M 2011 Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners. Thyroid 21:151–160. Link, Google Scholar10 The American Thyroid Association Taskforce on Radioiodine SafetySisson JCFreitas JMcDougall IRDauer LTHurley JRBrierley JDEdinboro CHRosenthal DThomas MJWexler JAAsamoah EAvram AMMilas MGreenlee C2011Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid AssociationThyroid21335346.10. The American Thyroid Association Taskforce on Radioiodine Safety; Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ, Wexler JA, Asamoah E, Avram AM, Milas M, Greenlee C 2011 Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid 21:335–346. Link, Google Scholar11 Promberger ROtt JKober FKarik MFreissmuth MHermann M2011Normal parathyroid hormone levels do not exclude permanent hypoparathyroidism after thyroidectomyThyroid21145150.11. Promberger R, Ott J, Kober F, Karik M, Freissmuth M, Hermann M 2011 Normal parathyroid hormone levels do not exclude permanent hypoparathyroidism after thyroidectomy. Thyroid 21:145–150. Link, Google Scholar12 Surks MIOrtiz EDaniels GHSawin CTCol NFCobin RHFranklyn JAHershman JMBurman KDDenke MAGorman CCooper RSWeissman NJ2004Subclinical thyroid disease: scientific review and guidelines for diagnosis and managementJAMA291228238.12. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228–238. Crossref, Medline, Google Scholar13 Gharib HTuttle RMBaskin HJFish LHSinger PAMcDermott MT2005Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine SocietyThyroid152428.13. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT 2005 Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society. Thyroid 15:24–28. Link, Google ScholarFiguresReferencesRelatedDetailsCited ByHiccups as a Rare Presentation of Thyrotoxicosis Triaged by an Epidural Steroid InjectionCureus, Vol. 5Changes in thyroid hormones in patients with chronic acalculous cholecystitis in the practice of a family doctor1 January 2020 | The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", No. 40Prevalence and pattern of thyroid disorders among patients attending University of Nigeria Teaching Hospital, Enugu, Southeastern NigeriaNigerian Medical Journal, Vol. 60, No. 2Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study Vishnu Sundaresh, Juan P. Brito, Prabin Thapa, Rebecca S. Bahn, and Marius N. Stan1 April 2017 | Thyroid, Vol. 27, No. 4Current trends in antithyroid drug treatment of Graves' disease14 September 2016 | Expert Opinion on Pharmacotherapy, Vol. 17, No. 15HyperthyroidismThe Lancet, Vol. 388, No. 10047Homeostatic Control of the Thyroid–Pituitary Axis: Perspectives for Diagnosis and Treatment20 November 2015 | Frontiers in Endocrinology, Vol. 6Poly-autoimmunity in patients with myasthenia gravis: A single-center experience14 April 2015 | Autoimmunity, Vol. 48, No. 6Diagnosis and Endocrine Management of Graves' Disease24 October 2014Clinical Evaluation of Various Thyroid Hormones on Thyroid FunctionInternational Journal of Endocrinology, Vol. 2014Endocrine emergencies in pregnancyBest Practice & Research Clinical Obstetrics & Gynaecology, Vol. 27, No. 6Diagnosis and management of Graves disease: a global overview15 October 2013 | Nature Reviews Endocrinology, Vol. 9, No. 12TSH receptor autoantibody immunoassay in patients with Graves' disease: Improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysisAutoimmunity Reviews, Vol. 12, No. 2 Volume 21Issue 6Jun 2011 InformationCopyright 2011, Mary Ann Liebert, Inc.To cite this article:Elizabeth N. Pearce, James V. Hennessey, and Michael T. McDermott.New American Thyroid Association and American Association of Clinical Endocrinologists Guidelines for Thyrotoxicosis and Other Forms of Hyperthyroidism: Significant Progress for the Clinician and a Guide to Future Research.Thyroid.Jun 2011.573-576.http://doi.org/10.1089/thy.2011.0104Published in Volume: 21 Issue 6: June 10, 2011PDF download
Referência(s)